Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Integra Lifesciences Increases Guidance

Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion – $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS
byBenzinga Newsdesk
October 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion – $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS outlook to $3.29 – $3.33 versus an estimate of $3.24.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts